|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's range||77.17 - 77.91|
|52-week range||74.09 - 94.26|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||7.59|
|Forward dividend & yield||3.33 (4.25%)|
|Ex-dividend date||08 Mar 2022|
|1y target est||102.00|
On Sept. 19, Novartis (NYSE: NVS) shared positive news with investors regarding the clinical trial results for its biosimilar drug candidate to Amgen's (NASDAQ: AMGN) osteoporosis medicine Prolia. With Prolia set to lose exclusivity in the U.S. in 2025, Novartis could be close to booking some revenue from its biosimilar drug. Let's go over the outcome of the clinical trial and the U.S. osteoporosis market to figure this out.
NVS vs. RHHBY: Which Stock Is the Better Value Option?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.